Some researchers have discussed the potential repurposing of GLP‐1 receptor agonists for the treatment of COVID‐19, citing their ability to exert a pulmonary protective effect by stimulating the angiotensin‐converting enzyme 2 (ACE2)/Angiotensin (1–7)/MasR axis.18 Here, MAS1L is linked to COVID-19.